GV was among the investors in a series A round led by Andreessen Horowitz closed three years after the gene therapy developer's launch.
US-based gene therapy developer Dyno Therapeutics completed a $100m series A round yesterday that included GV, a corporate venturing subsidiary of internet and technology group Alphabet.
Venture capital firm Andreessen Horowitz led the round, which also featured life sciences investment firm Casdin Capital and VC firms Obvious Ventures, Lux Capital, CRV and KdT Ventures as well as investment firm Polaris Partners.
Dyno’s CapsidMap platform optimises adeno-associated virus capsid vectors, applying artificial intelligence and machine learning to the development of gene…
